Search for: "Anda Inc." Results 41 - 60 of 960
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Jan 2020, 9:10 pm by Patent Docs
The issue arose in ANDA litigation, where the District Court found claim 6 of U.S. [read post]
20 Jun 2013, 1:00 am by Courtenay Brinckerhoff
Actavis, Inc., the Supreme Court held that reverse payment (“pay-for-delay”) settlement agreements made in the context of settling Hatch-Waxman ANDA litigation should be evaluated for antitrust violations under a “rule of reason” analysis. [read post]
1 Sep 2015, 9:59 pm by Patent Docs
Patent No. 7,772,209, owned by Lilly, would be infringed by the ANDA products for which Defendants Teva Parenteral Medicines, Inc.; Teva Pharmaceuticals USA, Inc.; APP Pharmaceuticals, LLC; Barr Laboratories, Inc.; and Pliva Hrvatska D.O.O. sought approval to market (opinion).... [read post]
6 May 2019, 9:58 pm by Patent Docs
The case arose in ANDA litigation over Mallinckrodt's U.S. [read post]
3 Jul 2012, 8:18 pm by Patent Docs
By Andrew Williams -- On Monday, in Sciele Pharma Inc. v. [read post]
24 Feb 2009, 9:43 pm
Food and Drug Administration from approving the Abbreviated New Drug Application (ANDA) filed by Defendant-Appellant Teva Pharmaceuticals USA, Inc. [read post]
7 Aug 2018, 8:20 am by RT
ANI Pharmaceuticals, Inc., 2018 WL 3677923, No. 17-4910 (D. [read post]
20 Aug 2020, 9:59 pm by Patent Docs
Noonan -- ANDA litigation, pursuant to the Hatch-Waxman Act, has become more complicated over the years since enactment of the statute in 1984, with more patents being asserted and more parties participating over the opportunity to market a generic version of a branded, innovator drug. [read post]
11 Aug 2010, 9:55 pm by Patent Docs
By Donald Zuhn -- In Adams Respiratory Therapeutics, Inc. v. [read post]
18 Aug 2022, 11:39 am by Eileen McDermott
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]